Selective Serotonin Reuptake Inhibitors Reduce the Attack Frequency in Familial Mediterranean Fever

Accession number;07A0040436
Title;Selective Serotonin Reuptake Inhibitors Reduce the Attack Frequency in Familial Mediterranean Fever
Author; ONAT AHMET MESUT (Department of Rheumatology, Gaziantep University Hospitals) OEZTUERK MEHMET AKIF (Department of Rheumatology, Gazi University Hospitals) OEZCAKAR LEVENT (Department of Physical Medicine and Rehabilitation, Hacettepe University Hospitals) UERETEN KEMAL (Department of Rheumatology, Etlik Social Security Hospital) KAYMAK SEMRA ULUSOY (Department of Psychiatry, Hacettepe University Hospitals) KIRAZ SEDAT (Department of Rheumatology, Hacettepe University Hospitals) ERTENLI IHSAN (Department of Rheumatology, Hacettepe University Hospitals) MERAL CALGUENERI (Department of Rheumatology, Hacettepe University Hospitals)
Journal Title;Tohoku J Exp Med
Journal Code:G0649A
ISSN:0040-8727
VOL.211;NO.1;PAGE.9-14 (J-STAGE)(2007)
Figure&Table&Reference;TBL.2, REF.31
Pub. Country;Japan
Language;English
Abstract;Familial Mediterranean Fever (FMF) is characterized by recurrent acute attacks of fever and serositis, and colchicine is the primary treatment. The pathogenesis of the disease has not been fully understood. Resistance to colchicine remains to be a problem in up to 30% of the patients and yet there seems to be no alternative treatment. In this study our objective was to investigate whether a selective serotonin re-uptake inhibitor (SSRI) could affect the attack frequency and acute phase response in FMF patients who were unresponsive to colchicine. We retrospectively evaluated the hospital files of 11 colchicine-unresponsive FMF patients who had been treated with SSRIs. According to the records and re-evaluation of the patients, the total number of the FMF attacks was calculated before and after the SSRI, adjunct to colchicine. The laboratory values including erythrocyte sedimentation rate, C-reactive protein, fibrinogen and white blood cell counts were also noted before and after the SSRI treatment from their hospital files. The mean attack frequency before adding SSRI to colchicine was 8.09 .+-. 3.53 per 6 months, and at the end of this period there was a great decline in the number of mean attack frequency (0.36 .+-. 0.50 attacks per 6 months) (p < 0.001). Acute phase reactants were significantly decreased after SSRI treatment (p < 0.001). All of the colchicine-unresponsive patients had depression and 3 of those patients also had fibromyalgia. SSRIs appear to be useful adjuncts in the management of FMF patients who continue to have attacks despite regular colchicine treatment. (Author abst.)
FULLTEXT